Your browser doesn't support javascript.
loading
Incidence, risk factors and outcomes of sinusoidal obstruction syndrome after haploidentical allogeneic stem cell transplantation.
Cai, Xuan; Wu, Jin; Gui, Ruo-Yun; Huang, Qiu-Sha; Liu, Xiao; Qin, Ya-Zhen; Wang, Jing-Zhi; Zeng, Qiao-Zhu; Jiang, Qian; Jiang, Hao; Lu, Jin; Wang, Jing-Bo; Gao, Li; Zhang, Xi; Zhang, Hong-Yu; Feng, Jia; Zhao, Xiang-Yu; Chang, Ying-Jun; Liu, Yan-Rong; Xu, Lan-Ping; Liu, Kai-Yan; Huang, Xiao-Jun; Zhang, Xiao-Hui.
Affiliation
  • Cai X; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Wu J; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Gui RY; Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.
  • Huang QS; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Liu X; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Qin YZ; Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.
  • Wang JZ; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Zeng QZ; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Jiang Q; Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.
  • Jiang H; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Lu J; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Wang JB; Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.
  • Gao L; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Zhang X; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Zhang HY; Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.
  • Feng J; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Zhao XY; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Chang YJ; Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.
  • Liu YR; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Xu LP; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
  • Liu KY; Collaborative Innovation Centre of Hematology, Peking University, Beijing, China.
  • Huang XJ; Peking University People's Hospital, Peking University Institute of Hematology, No. 11 Xizhimen South Street, Xicheng District, Beijing, China.
  • Zhang XH; Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation, Beijing, China.
Ann Hematol ; 98(7): 1733-1742, 2019 Jul.
Article in En | MEDLINE | ID: mdl-31053879
ABSTRACT
Hepatic sinusoidal obstruction syndrome (SOS) has been rarely studied after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (allo-HSCT). We performed a retrospective multicentre study on patients with SOS after allo-HSCT in China. The incidence, risk factors, and outcomes were compared between HID HSCT and matched related donor (MRD) HSCT. SOS developed in 0.4% of patients (HIDs 0.4%, MRDs 0.5%, p = 0.952) at a median time of 21.50 days (range, 1-55) after allo-HSCT (HIDs 24 days, MRDs 20 days, p = 0.316). For patients diagnosed with SOS, the 2-year cumulative incidence of relapse was 22.7% and 22.4% in patients receiving HID and MRD transplantation, respectively (p = 0.584). Overall survival (OS) at 2 year was 10.4% and 38.5% in the two groups (p = 0.113). The transplant-related mortality (TRM) at 100 days was 60.9% in the HID group and 38.5% in the MRD group (p = 0.178). According to the multivariate analyses, significant independent risk factors for the occurrence of SOS were delayed platelet engraftment (p = 0.007) and advanced disease status at the time of HSCT (p = 0.009). The outcomes of SOS after HID HSCT are similar to those after MRD HSCT.
Subject(s)
Key words

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue Donors / Hepatic Veno-Occlusive Disease / Hematopoietic Stem Cell Transplantation / Transplantation Conditioning Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2019 Document type: Article Affiliation country:

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Tissue Donors / Hepatic Veno-Occlusive Disease / Hematopoietic Stem Cell Transplantation / Transplantation Conditioning Type of study: Etiology_studies / Incidence_studies / Observational_studies / Prognostic_studies / Risk_factors_studies Limits: Adolescent / Adult / Child / Female / Humans / Male / Middle aged Country/Region as subject: Asia Language: En Journal: Ann Hematol Journal subject: HEMATOLOGIA Year: 2019 Document type: Article Affiliation country:
...